Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism

Recommendation is an important step toward potential public reimbursement for eligible adults whose chronic hypoparathyroidism is not adequately controlled with conventional therapy MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath® (palopegteriparatide injection) […]